stockportfolio.pro
Stocks / CATX vs EPRX
CATX vs EPRX
Perspective Therapeutics, Inc. and Eupraxia Pharmaceuticals Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Perspective Therapeutics, Inc. (CATX) | Eupraxia Pharmaceuticals Inc. (EPRX) | |
|---|---|---|
| Market cap | $0.3B | $0.4B |
| Revenue (latest FY) | $884,000 | $0 |
| Net income (latest FY) | $-103.12M | $-38.58M |
| Revenue growth (5y CAGR) | -38.5% | — |
| Net margin | -11665.3% | — |
| Return on equity | -49.8% | -47.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CATX — free Open EPRX — freeFrequently asked questions
Which is bigger, CATX or EPRX?
Eupraxia Pharmaceuticals Inc. is larger by market capitalization — $0.4B versus $0.3B.
Which grows faster, CATX or EPRX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.